An Anti-Intuitive Phenomenon
Many psychiatric medications are taken only once daily, yet the drugs themselves often have relatively short half-lives. Take bupropion—a norepinephrine-dopamine reuptake inhibitor (NDRI) used for depression, smoking cessation, and ADHD. Its immediate-release formulation has a half-life of approximately 21 hours. By classic pharmacokinetic principles, it should be dosed three times daily (TID) to maintain steady-state concentrations. Yet clinically, bupropion XL (extended-release) is prescribed once daily.
The secret lies not in extended-release technology alone, but in this: once ingested, bupropion is converted by the liver (via CYP2B6) into “hydroxybupropion”—a metabolite whose antidepressant activity is even stronger than the parent drug, with a half-life of roughly 20 hours, seamlessly maintaining therapeutic coverage.
In other words, what truly sustains efficacy inside the body isn’t just the pill you swallow—it’s what it transforms into after metabolism.
Mechanism: The Parent Drug Is the “Courier,” the Metabolite Does the Work
Ordinary drugs rely on their own half-life to maintain concentration. Short half-life means frequent re-dosing. The “active metabolite” mechanism works differently:
- The parent drug is absorbed into the bloodstream and exerts its initial effect;
- Hepatic enzymes convert the parent drug into a metabolite that retains pharmacological activity;
- This metabolite has a longer half-life than the parent drug, producing a smooth, gradual concentration curve;
- Together, the two extend the therapeutic window → less frequent dosing.
It’s as if the parent drug is a “courier” that delivers its payload and then quickly exits, while the delivered goods (the metabolite) keep working. Extended-release formulations (XL/SR) control the parent drug’s release rate, and the active metabolite controls the overall duration of effect—only when both layers combine can once-daily dosing be achieved.
Representative Drugs Using This Mechanism
Bupropion is far from alone. Several other drugs rely on active metabolites to compress dosing frequency down to once daily (or even less):
| Drug | Active Metabolite | Metabolite Half-Life | Dosing Frequency |
|---|---|---|---|
| Bupropion | Hydroxybupropion | ~20 h | XL once daily |
| Fluoxetine (Prozac) | Norfluoxetine | 7–15 days | The most extreme case—can be dosed weekly |
| Aripiprazole | Dehydroaripiprazole | ~94 h (about 4 days) | Once daily |
| Venlafaxine | Desvenlafaxine | ~11 h (parent drug only 5 h) | ER once daily |
| Risperidone | 9-Hydroxyrisperidone (=paliperidone) | ~23 h | ER once daily |
A few details worth noting:
- Fluoxetine is the extreme competitor on this track. Its active metabolite, norfluoxetine, has a half-life of 7–15 days—the longest among all SSRIs. Active drug can persist in the body for weeks after discontinuation. This is also why fluoxetine’s discontinuation syndrome is relatively mild, but it means drug-drug interactions (particularly CYP2B6/3A4 inhibition) take weeks to fully resolve.
- Aripiprazole’s metabolite, dehydroaripiprazole, has a half-life of about 94 hours and possesses antipsychotic activity on its own. Its concentration can reach 30–40% of the parent drug’s level. Such a long tail makes once-daily dosing feasible and explains why symptoms don’t rebound immediately after discontinuation.
- The active metabolites of venlafaxine and risperidone are so potent that pharmaceutical companies developed them into independent new drugs: desvenlafaxine (brand name Pristiq) and paliperidone (brand name Invega). It’s as if the companies said: “Since the metabolite is the real powerhouse, just take the powerhouse directly and skip the parent drug’s conversion step.” This is the most thorough commercial exploitation of this mechanism.
The Mechanism Isn’t All Advantage
The active metabolite mechanism brings more convenience than “swallow fewer pills”—it also carries costs:
- Slower onset: Accumulating the metabolite to steady state takes 4–5 half-lives. Fluoxetine may require a full month to reach steady state, widening the titration window.
- Prolonged washout: A long half-life means the body clears the drug slowly after discontinuation. The upside is milder discontinuation symptoms; the downside is that adverse effects can’t be rapidly “cleared out” if they occur.
- Long drug-interaction window: Norfluoxetine’s inhibition of CYP2B6/3A4 can persist for weeks. Any other drugs metabolized by these enzymes introduced during that period require dose reassessment.
- Amplified interindividual variability: Metabolic capacity depends on hepatic enzyme phenotype. Bupropion, for example, relies on CYP2B6. Slow metabolizers generate the active metabolite more slowly, producing blood concentration curves that differ significantly from fast metabolizers—the same pill can yield noticeably different effects across individuals.
Summary
The fact that “one pill lasts a whole day” often rests on more than a single mechanism. Extended-release formulations control the release rate; active metabolites extend the therapeutic window. Only the combination of both achieves once-daily dosing. Bupropion, fluoxetine, aripiprazole, venlafaxine, and risperidone are all representatives of this approach—and for the latter two, the metabolites were so effective that they were developed into standalone medications.
The practical value of understanding this mechanism is that it explains why some drugs don’t need to be redosed every 8 hours, and it also signals the pharmacokinetic timescales to keep in mind when adjusting, discontinuing, or switching medications—not based on the parent drug’s half-life, but on that “relay-runner” metabolite doing the real work.
This article is a compilation of pharmacological mechanism references and does not constitute medical advice. Any medication adjustments must be evaluated and confirmed by a psychiatrist.